3 period full replicate [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2015-06-24 16:38 (3226 d 16:05 ago) – Posting: # 14977
Views: 28,931

Dear Dr_Dan!

❝ From a leading European regulatory authority I just recieved the information that a 3-period full replicate design (two sequences: T-R-T and R-T-R) for a bioequivalence study will not be accepted. The reason is that for a full replicate design R as well as T need to be repclicated and this is only possible with the respective sequences (so TTRR etc.) ...


Seems the story "Potvin C is not valid in Europe" is duplicated here on another field!

The full replicate 3-period design has the sequences TRT / RTR as is stated in your post and of course has T and R replicated. Not in each subject, but if balanced in half of ntotal each. And this design of course allows the evaluation of the intra-subject variabilities of T and R separately.

So what's the problem of the "leading European regulatory authority"?
Especially in the light of ElMaestro's remark that only the intra-subject variability of R is of any regulatory concern if scaled ABE is aimed for :confused:.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,659 registered users;
65 visitors (0 registered, 65 guests [including 2 identified bots]).
Forum time: 08:44 CEST (Europe/Vienna)

So far as I can remember,
there is not one word in the Gospels
in praise of intelligence.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5